Biocryst Pharmaceuticals (BCRX) Depreciation and Depletion (2025 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Depreciation and Depletion of $461000.0 for Q1 2026, up 39.27% on a QoQ basis from $331000.0 in Q1 2025, and up 39.27% year-over-year from $331000.0 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Depreciation and Depletion (2025 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Depreciation and Depletion history runs 2 years deep, the most recent figure standing at $461000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 36.00 Mn |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | 21.60 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 28.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.37 Bn | 2.30 Bn | 151.04 Mn | 461,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 461,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Mar 31, 2025 | 331,000.00 |